 Tejas Patil
Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 33 | 2025 | 1081 | 5.860 |
Why?
| | Lung Neoplasms | 35 | 2025 | 2526 | 4.200 |
Why?
| | Aniline Compounds | 7 | 2025 | 102 | 1.790 |
Why?
| | Acrylamides | 6 | 2025 | 57 | 1.780 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2025 | 1692 | 1.620 |
Why?
| | Mutation | 17 | 2025 | 3958 | 1.540 |
Why?
| | ErbB Receptors | 15 | 2025 | 614 | 1.370 |
Why?
| | Protein-Tyrosine Kinases | 7 | 2023 | 434 | 0.960 |
Why?
| | Proto-Oncogene Proteins | 7 | 2023 | 648 | 0.950 |
Why?
| | Pemetrexed | 1 | 2024 | 33 | 0.910 |
Why?
| | Immunoconjugates | 1 | 2025 | 114 | 0.850 |
Why?
| | Protein Kinase Inhibitors | 11 | 2025 | 916 | 0.800 |
Why?
| | Brain Neoplasms | 6 | 2024 | 1238 | 0.780 |
Why?
| | Pleural Neoplasms | 2 | 2024 | 25 | 0.710 |
Why?
| | Antibodies, Monoclonal | 2 | 2025 | 1430 | 0.700 |
Why?
| | Pyrimidines | 7 | 2025 | 470 | 0.630 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2021 | 801 | 0.620 |
Why?
| | Receptor, ErbB-2 | 2 | 2019 | 341 | 0.570 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 12 | 0.510 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 93 | 0.470 |
Why?
| | Aged, 80 and over | 8 | 2025 | 7635 | 0.450 |
Why?
| | Adenocarcinoma | 2 | 2018 | 940 | 0.440 |
Why?
| | Medical Oncology | 3 | 2025 | 289 | 0.440 |
Why?
| | Mesothelioma | 2 | 2024 | 44 | 0.410 |
Why?
| | Middle Aged | 22 | 2025 | 33479 | 0.380 |
Why?
| | Disease Progression | 4 | 2025 | 2757 | 0.370 |
Why?
| | Retrospective Studies | 18 | 2025 | 15657 | 0.370 |
Why?
| | Aged | 17 | 2025 | 23961 | 0.360 |
Why?
| | Indoles | 5 | 2025 | 412 | 0.360 |
Why?
| | Gene Rearrangement | 4 | 2022 | 150 | 0.340 |
Why?
| | Neoplasm Staging | 6 | 2024 | 1389 | 0.340 |
Why?
| | B7-H1 Antigen | 2 | 2025 | 217 | 0.330 |
Why?
| | Humans | 43 | 2025 | 137585 | 0.330 |
Why?
| | Antineoplastic Agents | 5 | 2024 | 2129 | 0.320 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 267 | 0.310 |
Why?
| | Pyrazoles | 3 | 2023 | 423 | 0.300 |
Why?
| | Lung | 2 | 2018 | 4060 | 0.300 |
Why?
| | Female | 24 | 2025 | 73304 | 0.270 |
Why?
| | Survival Rate | 6 | 2020 | 1972 | 0.250 |
Why?
| | Adult | 12 | 2025 | 37929 | 0.250 |
Why?
| | Neoplasm Metastasis | 3 | 2024 | 658 | 0.250 |
Why?
| | Male | 21 | 2025 | 67762 | 0.240 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2020 | 683 | 0.240 |
Why?
| | Thymus Neoplasms | 1 | 2025 | 25 | 0.240 |
Why?
| | Central Nervous System | 3 | 2023 | 258 | 0.240 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2025 | 249 | 0.240 |
Why?
| | Thymoma | 1 | 2025 | 36 | 0.240 |
Why?
| | Biomarkers, Tumor | 3 | 2024 | 1276 | 0.230 |
Why?
| | Thoracic Neoplasms | 1 | 2025 | 37 | 0.230 |
Why?
| | Proto-Oncogene Proteins c-met | 2 | 2023 | 75 | 0.230 |
Why?
| | Neoadjuvant Therapy | 2 | 2024 | 404 | 0.220 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 411 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2021 | 36 | 0.220 |
Why?
| | Oncogenes | 3 | 2022 | 116 | 0.210 |
Why?
| | Oncogene Addiction | 1 | 2023 | 5 | 0.200 |
Why?
| | Research Personnel | 1 | 2025 | 173 | 0.200 |
Why?
| | Radiosurgery | 2 | 2024 | 344 | 0.200 |
Why?
| | Soft Tissue Neoplasms | 1 | 2023 | 115 | 0.190 |
Why?
| | Chemoradiotherapy | 1 | 2024 | 225 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1050 | 0.190 |
Why?
| | Acetonitriles | 1 | 2021 | 11 | 0.180 |
Why?
| | Sarcoma | 1 | 2023 | 188 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2023 | 247 | 0.170 |
Why?
| | Pyridines | 2 | 2021 | 506 | 0.170 |
Why?
| | Circulating Tumor DNA | 1 | 2020 | 34 | 0.160 |
Why?
| | Lactams | 1 | 2019 | 20 | 0.160 |
Why?
| | Gene Amplification | 1 | 2019 | 104 | 0.160 |
Why?
| | Lactams, Macrocyclic | 1 | 2019 | 49 | 0.160 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 9 | 0.160 |
Why?
| | Aminopyridines | 1 | 2019 | 98 | 0.150 |
Why?
| | Genes, erbB-1 | 1 | 2018 | 17 | 0.150 |
Why?
| | Piperazines | 1 | 2021 | 350 | 0.150 |
Why?
| | Neoplasms | 2 | 2024 | 2671 | 0.150 |
Why?
| | Oncogene Proteins | 1 | 2018 | 59 | 0.150 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 98 | 0.140 |
Why?
| | Transcriptome | 1 | 2024 | 971 | 0.140 |
Why?
| | Thromboembolism | 1 | 2018 | 119 | 0.140 |
Why?
| | Disease-Free Survival | 2 | 2017 | 686 | 0.140 |
Why?
| | Computed Tomography Angiography | 1 | 2018 | 129 | 0.140 |
Why?
| | Biomarkers, Pharmacological | 1 | 2017 | 28 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 273 | 0.130 |
Why?
| | Smad4 Protein | 1 | 2017 | 38 | 0.130 |
Why?
| | Gene Deletion | 1 | 2018 | 391 | 0.130 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 72 | 0.130 |
Why?
| | Prognosis | 3 | 2020 | 4030 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 190 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2020 | 5131 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 1079 | 0.120 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 806 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 2 | 2022 | 2691 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2018 | 786 | 0.100 |
Why?
| | Gene Fusion | 2 | 2023 | 27 | 0.090 |
Why?
| | Incidence | 1 | 2018 | 2804 | 0.090 |
Why?
| | Smoking | 1 | 2018 | 1627 | 0.090 |
Why?
| | Quality of Life | 1 | 2022 | 2892 | 0.080 |
Why?
| | Survival Analysis | 2 | 2025 | 1325 | 0.080 |
Why?
| | Biomarkers | 1 | 2017 | 4149 | 0.060 |
Why?
| | Myasthenia Gravis | 1 | 2025 | 23 | 0.060 |
Why?
| | Pleura | 1 | 2024 | 23 | 0.050 |
Why?
| | Consolidation Chemotherapy | 1 | 2024 | 10 | 0.050 |
Why?
| | Carbazoles | 1 | 2024 | 83 | 0.050 |
Why?
| | Tropomyosin | 1 | 2023 | 14 | 0.050 |
Why?
| | Receptor, trkA | 1 | 2023 | 18 | 0.050 |
Why?
| | Canada | 1 | 2025 | 418 | 0.050 |
Why?
| | Peritoneum | 1 | 2023 | 44 | 0.050 |
Why?
| | Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 12 | 0.050 |
Why?
| | Platinum | 1 | 2023 | 50 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2023 | 183 | 0.050 |
Why?
| | Taxoids | 1 | 2023 | 102 | 0.050 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2022 | 18 | 0.050 |
Why?
| | Piperidines | 1 | 2024 | 206 | 0.050 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2023 | 93 | 0.050 |
Why?
| | Exons | 1 | 2023 | 355 | 0.050 |
Why?
| | Young Adult | 1 | 2018 | 13209 | 0.050 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2023 | 215 | 0.050 |
Why?
| | Appendiceal Neoplasms | 1 | 2021 | 27 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 429 | 0.040 |
Why?
| | Meningeal Neoplasms | 1 | 2021 | 100 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 234 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2024 | 10811 | 0.040 |
Why?
| | Protein Conformation | 1 | 2021 | 934 | 0.040 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2017 | 17 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1774 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2024 | 1069 | 0.030 |
Why?
| | Etoposide | 1 | 2017 | 158 | 0.030 |
Why?
| | Cranial Irradiation | 1 | 2017 | 70 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 224 | 0.030 |
Why?
| | Registries | 1 | 2024 | 2035 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 889 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2017 | 142 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2017 | 179 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 641 | 0.030 |
Why?
| | Genomics | 1 | 2020 | 795 | 0.030 |
Why?
| | DNA Repair | 1 | 2017 | 231 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1509 | 0.030 |
Why?
| | United States | 2 | 2025 | 14841 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 657 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 480 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5742 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1236 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1357 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 804 | 0.030 |
Why?
| | Mass Screening | 1 | 2020 | 1287 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1396 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3566 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3284 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2426 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 6763 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6828 | 0.020 |
Why?
| | Adolescent | 1 | 2023 | 21513 | 0.010 |
Why?
| | Signal Transduction | 1 | 2017 | 5079 | 0.010 |
Why?
| | Child | 1 | 2023 | 21935 | 0.010 |
Why?
|
|
Patil's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|